The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents

doi:10.4252/wjsc.v2.i1.5

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5012)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

309

HTML

4511

Figures (1-3)

192

Sum=5012

Feb 26, 2010 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (38)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Feb 26, 2010; 2(1): 5-12
Published online Feb 26, 2010. doi: 10.4252/wjsc.v2.i1.5

Full Size Figure Download Figure

Figure 3 Mesenchymal stem cells as vehicle for anticancer drug. In the Figure are indicated the vectors used to engineer MSCs and the “therapeutical genes”. Target cancer cells are in parenthesis. MSCs: Mesenchymal stem cells; IL12: Interleukin-12; IFN-γ: Interferon-gamma; TRAIL: Tumor necrosis (TNF)-related apoptosis-inducing ligand.

Citation: Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells 2010; 2(1): 5-12
URL: https://www.wjgnet.com/1948-0210/full/v2/i1/5.htm
DOI: https://dx.doi.org/10.4252/wjsc.v2.i1.5